Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Ruxolitinib has been a primary treatment for myelofibrosis for over ten years.
• Recent years have seen regulatory approvals for other Janus kinase (JAK) inhibitors like fedratinib and pacritinib, with momelotinib anticipated.
• The complex nature of myelofibrosis makes defining ruxolitinib failure challenging, necessitating clear management strategies.

Purpose of the Study:

• To establish consensus on managing myelofibrosis patients refractory to, inadequately responding to, or intolerant of ruxolitinib.
• To address the critical need for unified approaches given the expanding therapeutic landscape of JAK inhibitors.
• To provide guidance on optimal patient care considering new treatment options.

Main Methods:

• A consensus discussion among academic and community physician experts, a pharmacist, and an advanced practice provider.
• Review of clinical presentations and management nuances of myelofibrosis.
• Deliberation on strategies for patients with ruxolitinib failure.

Main Results:

• Areas of consensus were identified regarding the management of ruxolitinib failure in myelofibrosis.
• The panel highlighted situations where continuing ruxolitinib with an additional agent is appropriate, particularly for anemia.
• Switching to an alternative therapy was recognized as a valid strategy in other scenarios.

Conclusions:

• Optimal care for myelofibrosis patients requires careful consideration of ruxolitinib failure management.
• The expanding availability of JAK inhibitors necessitates updated clinical practice guidelines.
• Further data is needed to inform evidence-based decisions in specific patient subgroups.